Virtus ETF Advisers’s Vanda Pharmaceuticals VNDA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-48,530
| Closed | -$210K | – | 464 |
|
|
2023
Q3 | $210K | Sell |
48,530
-6,275
| -11% | -$34.9K | 0.13% | 244 |
|
|
2023
Q2 | $361K | Buy |
54,805
+12,265
| +29% | +$78.6K | 0.21% | 146 |
|
|
2023
Q1 | $289K | Buy |
42,540
+751
| +2% | +$5.28K | 0.16% | 237 |
|
|
2022
Q4 | $309K | Buy |
41,789
+16,855
| +68% | +$164K | 0.16% | 251 |
|
|
2022
Q3 | $246K | Buy |
24,934
+365
| +1% | +$3.85K | 0.1% | 293 |
|
|
2022
Q2 | $268K | Buy |
24,569
+1,234
| +5% | +$12.8K | 0.1% | 284 |
|
|
2022
Q1 | $264K | Hold |
23,335
| – | – | 0.12% | 182 |
|
|
2021
Q4 | $366K | Sell |
23,335
-358
| -2% | -$6.24K | 0.14% | 179 |
|
|
2021
Q3 | $406K | Sell |
23,693
-2,177
| -8% | -$38.1K | 0.18% | 172 |
|
|
2021
Q2 | $556K | Sell |
25,870
-22,044
| -46% | -$394K | 0.23% | 122 |
|
|
2021
Q1 | $720K | Buy |
47,914
+1,312
| +3% | +$21.2K | 0.3% | 104 |
|
|
2020
Q4 | $612K | Sell |
46,602
-8,175
| -15% | -$98.4K | 0.25% | 106 |
|
|
2020
Q3 | $529K | Buy |
54,777
+4,614
| +9% | +$49.3K | 0.28% | 126 |
|
|
2020
Q2 | $574K | Buy |
50,163
+14,995
| +43% | +$170K | 0.27% | 126 |
|
|
2020
Q1 | $364K | Sell |
35,168
-2,968
| -8% | -$36.8K | 0.15% | 204 |
|
|
2019
Q4 | $626K | Sell |
38,136
-9,334
| -20% | -$141K | 0.1% | 181 |
|
|
2019
Q3 | $630K | Sell |
47,470
-7,974
| -14% | -$111K | 0.13% | 171 |
|
|
2019
Q2 | $781K | Buy |
+55,444
| New | +$882K | 0.16% | 187 |
|
|
2019
Q1 | – | Sell |
-22,661
| Closed | -$592K | – | 266 |
|
|
2018
Q4 | $592K | Sell |
22,661
-20,116
| -47% | -$473K | 0.1% | 48 |
|
|
2018
Q3 | $982K | Buy |
42,777
+2,882
| +7% | +$58.8K | 0.1% | 50 |
|
|
2018
Q2 | $760K | Sell |
39,895
-24,145
| -38% | -$404K | 0.67% | 64 |
|
|
2018
Q1 | $1.08M | Sell |
64,040
-3,773
| -6% | -$63.2K | 0.94% | 29 |
|
|
2017
Q4 | $1.03M | Sell |
67,813
-6,920
| -9% | -$103K | 1.29% | 12 |
|
|
2017
Q3 | $1.34M | Hold |
74,733
| – | – | 0.18% | 43 |
|
|
2017
Q2 | $1.22M | Buy |
74,733
+10,020
| +15% | +$144K | 0.18% | 37 |
|
|
2017
Q1 | $906K | Buy |
64,713
+6,223
| +11% | +$88.7K | 0.16% | 74 |
|
|
2016
Q4 | $933K | Buy |
58,490
+954
| +2% | +$15.3K | 0.28% | 63 |
|
|
2016
Q3 | $957K | Buy |
57,536
+7,249
| +14% | +$97.6K | 0.46% | 36 |
|
|
2016
Q2 | $563K | Sell |
50,287
-16,734
| -25% | -$162K | 0.42% | 33 |
|
|
2016
Q1 | $560K | Hold |
67,021
| – | – | 0.77% | 29 |
|
|
2015
Q4 | $624K | Buy |
+67,021
| New | +$669K | 1.71% | 16 |
|
Other funds holding VNDA
Virtus ETF Advisers's VNDA Position: Q4 2023 in Review
Virtus ETF Advisers sold out of Vanda Pharmaceuticals (VNDA) in Q4 2023, closing a stake of 48,530 shares — an estimated $210K sold.
Virtus ETF Advisers first reported a position in VNDA in Q4 2015 and held it in 31 quarters. The position peaked at $1.34M in Q3 2017. 157 funds tracked by Wall St. Rank hold VNDA as of Q4 2023.
- Virtus ETF Advisers reported no remaining Vanda Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
- Virtus ETF Advisers sold 48,530 Vanda Pharmaceuticals shares in Q4 2023, an estimated $210K.
- Virtus ETF Advisers first reported a position in Vanda Pharmaceuticals in Q4 2015 and held it in 31 quarters.
- Virtus ETF Advisers's Vanda Pharmaceuticals position peaked at $1.34M in Q3 2017.
- 157 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2023.
Based on Virtus ETF Advisers's 13F filing for Q4 2023, filed 15 Feb 2024.